The fields of tissue engineering (TE) and regenerative medicine (RegMed) 
Introduction

Regenerative medicine (RegMed) is an interdisciplinary field of research and clinical applications focused on the repair, replacement or regeneration of cells, tissues or organs to restore impaired function resulting from any cause, including congenital defects, disease, trauma and ageing. It uses a combination of several converging technological approaches, both existing and newly
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A brief review in the recent bibliography concerning advances in TE and RegMed would raise the impression that 'we are almost there', being able to produce tissue replacement 'off the shelf', in the near future for everyone in need [11, 14, 17, [19] [20] [21] [22] [23] [24] . Interestingly enough, that was exactly the spirit some 10 years ago [25, 26] . It seems -literally spoken -that we are able to fabricate constructs that 'look like tissue, smell like tissue and taste like tissue' but not some that also function equally like one. An ever perpetuating evolution is yet to bring the long awaited revolution in the health sector. More critically spoken, others have proclaimed that the time must come to 'stop tissue engineering and start engineering tissues' [27] . A brief historical tour of regeneration and RegMed constitutes along with a critical analysis of the present, the filter through which we put together the puzzle of its future.
Regeneration in the ancient world
The myth of the great Titan Prometheus, as introduced by Hesiod in his Theogony (8 th 
century B.C.) provides an icon for RegMed.
When he stole fire, a symbol for civilization and technology, to give it to mankind he received a cruel punishment [28] . Jupiter Descartes (1596 Descartes ( -1650 [42] . Because ectopic blastocyst injections were also found to generate teratomas it became soon evident that pluripotent cells could also be derived from blastocysts directly [43] . Soon the next logical step was undertaken, when Gail Martin [44] [4] . [52] . By the turn of the century, there were over 3000 people working in the sector, with funding exceeding US $580 million [53, 54] .
Regeneration in early research
In 1996, the Tissue Engineering Society International (TESi) was officially founded by Joseph and Charles Vacanti, and the Asian TE societies were incorporated in TESi by 2000. Soon thereafter, Raymund E. Horch and G. Björn Stark from Freiburg encouraged the foundation of the European branch of TESi the ETES, and they hosted in 2001 the TESi meeting in Germany. Time magazine described with a cover story, tissue engineers as the 'hottest job' for the future: 'With man-made skin already on the market and artificial cartilage not far behind, 25 years from now scientists expect to be pulling a pancreas out of a Petri dish'
The era of regenerative medicine
The transition from TE into RegMed was justified by dramatic developments in the financial, scientific and political landscape. [54] . [55] . Drug delivery systems and nanotechnology were developed and integrated in the design of biomaterials [56] . The paramount significance of angiogenic processes [23, 24, 57] for homeostasis, biointegration and upscaling of tissue engineered constructs became clear [19, [58] [59] [60] . Experimental activities were directed to encompass integrative strategies towards generation of autonomously vascularized bioartificial tissue elements [61, 62] (Fig. 2) . In addition tumour research was further advanced with the prospect of revolutionizing cancer treatment to round up progress in the biotechnological arena [8, 26] . [68] [69] [70] . As an example, preservation of cord blood stem cells is gaining popularity after promising results on their use for brain injury [71] and type 1 diabetes mellitus [72] as well as stroke [73] and hearing loss [74] .
From a financial point of view, the first years of the 21st century, anticipated to bring the biotechnological revolution, were characterized by a disconnect between expectations and reality. As Lysaght noted in 2004 '…Although aggregate development costs exceed $4.5 billion, the field has yet to produce a single profitable product'
On the scientific arena new technologies had come into play, with the very term TE being unable to accommodate them: The availability of human embryonic stem cells was bringing the cellular therapy at the front line of the field. Gene technology had come to a point, where a whole mammal could be cloned or genetically manipulated (the Monsanto swine case)
The capacity of liver to regenerate is known by millennia, but the dogma that heart is a nonregenerating organ has been only recently challenged. Lately, niches of putative cardiac stem cells were identified in the murine and human heart [76] [77] [78] . These data engender a new direction in RegMed basic research -the necessity to discover the natural microenvironment and consequently, to engineer the artificial support essential for stem cells to act [79] [80] [81] . Finally, heart diseases might be prone to therapy by means of a new line of cells, the unique cardiac telocytes (Fig. 4) responsible for a continuous regeneration in the mammalian heart [5, 10, 75, 82] 
